These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8683992)

  • 41. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
    Mohamed AN; Pemberton P; Zonder J; Schiffer CA
    Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
    Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relapse after allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia: cytogenetic analysis of 24 patients.
    Zaccaria A; Rosti G; Sessarego M; Frassoni F; Marmont A; Galimberti M; Baronciani D; Filippetti A; Di Bartolomeo P; Di Girolamo G
    Bone Marrow Transplant; 1988 Sep; 3(5):413-23. PubMed ID: 3056550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Tomás JF; López-Lorenzo JL; Requena MJ; Aguilar R; Steegmann JL; Cámara R; Alegre A; Arranz R; Figuera A; Fernández-Rañada JM
    Bone Marrow Transplant; 1998 Jul; 22(1):47-51. PubMed ID: 9678795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612).
    Slovak ML; Kopecky KJ; Wolman SR; Henslee-Downey JP; Appelbaum FR; Forman SJ; Blume KG
    Leuk Res; 1995 Jun; 19(6):381-8. PubMed ID: 7596150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
    Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
    Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
    Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
    Hehlmann R; Kister P; Willer A; Simon M; Schenk M; Seifarth W; Papakonstantinou G; Saussele S; Kolb HJ; Ansari H
    Leukemia; 1994 Apr; 8 Suppl 1():S127-32. PubMed ID: 8152279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
    Hehlmann R; Heimpel H; Griesshammer M; Kolb HJ; Heinze B; Hossfeld DK; Wickramanayake PD; Essers U; Thiele J; Georgii A
    Leukemia; 1992; 6 Suppl 3():110S-114S. PubMed ID: 1602805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
    Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
    Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
    Hehlmann R; Hochhaus A; Kolb HJ; Hasford J; Gratwohl A; Heimpel H; Siegert W; Finke J; Ehninger G; Holler E; Berger U; Pfirrmann M; Muth A; Zander A; Fauser AA; Heyll A; Nerl C; Hossfeld DK; Löffler H; Pralle H; Queisser W; Tobler A
    Blood; 1999 Dec; 94(11):3668-77. PubMed ID: 10572078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group.
    Blood; 1998 Apr; 91(8):2713-21. PubMed ID: 9531580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interferon-alpha in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies.
    Rosti G; De Vivo A; Zuffa E; Baccarani M
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S11-3. PubMed ID: 8769692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome.
    Beelen DW; Graeven U; Elmaagacli AH; Niederle N; Kloke O; Opalka B; Schaefer UW
    Blood; 1995 May; 85(10):2981-90. PubMed ID: 7742558
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicenter prospective study of interferon-alpha versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis.
    Ohnishi K; Ino T; Kishimoto Y; Usui N; Shimazaki C; Ohtake S; Taguchi H; Kusumoto S; Kuriyama K; Hotta T; Ohno R
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S59-64. PubMed ID: 11587369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Rios MB; Majlis A; Keating M; Freireich EJ; Kantarjian H
    J Clin Oncol; 1998 Oct; 16(10):3279-85. PubMed ID: 9779702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation.
    Higano CS; Raskind WH; Singer JW
    Blood; 1992 Sep; 80(6):1437-42. PubMed ID: 1520870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
    Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
    Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.
    Allan NC; Richards SM; Shepherd PC
    Lancet; 1995 Jun; 345(8962):1392-7. PubMed ID: 7760609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.